A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 1, 2018

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
LGL LeukemiaCTCL
Interventions
DRUG

BNZ132-1-40

Injectable PEGylated peptide antagonist that binds to the common gamma chain (γc) signaling receptor for the cytokines interleukin (IL)-2, IL-9, and IL-15

Trial Locations (4)

10101

City of Hope National Medical Center, Duarte

22908

University of Virginia Cancer Center, Charlottesville

33612

Moffitt Cancer Center, Tampa

43210

The James Cancer Center, Ohio State University, Columbus

Sponsors
All Listed Sponsors
lead

Bioniz Therapeutics

INDUSTRY

NCT03239392 - A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL | Biotech Hunter | Biotech Hunter